Delivery Order HT942525D0009-HT942525FE048
Award Date 9/19/25
Potential Completion Date 2/25/26
Potential Value $61K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for the supply of antibodies and antigens, with a ceiling value of $110,500.00. The contract was awarded by the Defense Health Agency, a defense agency, to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company specializing in antibody-based therapeutics and medical countermeasures. The contract has a firm fixed price pricing type and a completion date of December 4, 2025. This award does not have a set-aside designation. Mapp Biopharmaceutical has...
- This $38,243,034.02 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, which has no set-aside designation, is for the development of medical countermeasures through planned clinical trials and outbreak preparedness. This contract builds on...
- This is a $293,443,870.00 definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract is for the provision of therapeutic interventions and medical countermeasures against infectious diseases and biothreats, including viral hemorrhagic fevers like Ebola, Marburg, and Lassa, as well as botulinum neurotoxin. Mapp...
- This is a federal contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in the development of antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, valued at $6,173,324.00, is for research and development services during the base period, with a period of performance ending on August 31, 2017. The contract is a Cost Plus Fixed Fee Definitive...
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the Joint PEO Chemical and Biological Defense, a defense agency, to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The $999,927.74 Firm Fixed Price contract is for monthly status reports related to SBIR Phase II research and development efforts. Mapp Biopharmaceutical is a key player in advancing treatments for viral hemorrhagic fevers and other emerging infectious diseases,...
- This is a $62,511,942.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The contract is for the development of an anti-Sudan ebolavirus medical countermeasure, a critical public health and national security priority. Mapp Biopharmaceutical has a strong...
- This is a cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc. for the development of Mapp's therapeutic intervention MBP091 as an immunotherapy for the treatment of Marburg virus infection. The contract has a ceiling value of $299,045,139.03 and a completion date of July 31, 2036. No set-aside was used for this award. Mapp Biopharmaceutical is a biotechnology company that specializes in developing...
- This is a $16,413,163.00 Cost Plus Fixed Fee contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract is for the development of a pan-botulinum neurotoxin medical countermeasure, with a period of performance ending on June 30,...
- This is a $30,559,760.00 cost-plus-fixed-fee delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The contract is for the development of the MAPP biopharmaceutical Viral Hemorrhagic Fever (VHF) Medical Countermeasure (MCM) platform. This work is being performed under the Centers for Innovation in...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Genovac Antibody Discovery LLC, a self-certified small disadvantaged business, for the development and analysis of human monoclonal antibodies (mABs). The $180,000.00 contract supports the Walter Reed Army Institute of Research (WRAIR) and Armed Forces Research Institute of Medical Sciences (WRAIR-AFRIMS) programs. The contract has a base period of 1 year with two 1-year option periods and does not have a...